盐酸苯达莫司汀(美)

盐酸苯达莫司汀(美)

ID:36664154

大小:297.85 KB

页数:13页

时间:2019-05-13

盐酸苯达莫司汀(美)_第1页
盐酸苯达莫司汀(美)_第2页
盐酸苯达莫司汀(美)_第3页
盐酸苯达莫司汀(美)_第4页
盐酸苯达莫司汀(美)_第5页
资源描述:

《盐酸苯达莫司汀(美)》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、HIGHLIGHTSOFPRESCRIBINGINFORMATION-------------------------WARNINGSANDPRECAUTIONS---------------------Thesehighlightsdonotincludealltheinformationneededtouse•Myelosuppression:Maywarranttreatmentdelayordosereduction.TREANDAsafelyandeffectively.SeefullprescribinginformationforMonitorclosely

2、andrestarttreatmentbasedonANCandplateletcountTREANDA.recovery.Complicationsofmyelosuppressionmayleadtodeath.(5.1)•Infections:Monitorforfeverandothersignsofinfectionandtreat®TREANDA(bendamustinehydrochloride)forInjection,forintravenouspromptly.(5.2)infusion•InfusionReactionsandAnaphylaxis:

3、SevereanaphylacticreactionshaveInitialU.S.Approval:2008occurred.Monitorclinicallyanddiscontinuedrugforseverereactions.Ask----------------------------RECENTMAJORCHANGES-------------------------patientsaboutreactionsafterthefirstcycle.Considerpre-treatmentforWarningsandPrecautions,Extravasa

4、tion(5.7)01/2010cyclessubsequenttomilderreactions.(5.3)•TumorLysisSyndrome:Mayleadtoacuterenalfailureanddeath.Take----------------------------INDICATIONSANDUSAGE---------------------------precautionsinpatientsathighrisk.(5.4)TREANDAforInjectionisanalkylatingdrugindicatedfortreatmentof•Ski

5、nReactions:Discontinueforsevereskinreactions.CasesofSJSandpatientswith:TEN,somefatal,havebeenreportedwhenTREANDAwasadministered•Chroniclymphocyticleukemia(CLL).Efficacyrelativetofirstlineconcomitantlywithallopurinolandothermedicationsknowntocausethesetherapiesotherthanchlorambucilhasnotbe

6、enestablished.(1.1)syndromes.(5.5)•IndolentB-cellnon-Hodgkin’slymphoma(NHL)thathasprogressed•OtherMalignancies:Pre-malignantandmalignantdiseaseshavebeenduringorwithinsixmonthsoftreatmentwithrituximaborarituximabreported.(5.6)containingregimen.(1.2)•Extravasation:Takeprecautionstoavoidextr

7、avasation,including----------------------DOSAGEANDADMINISTRATION------------------------monitoringintravenousinfusionsiteduringandafteradministration.(5.7)ForCLL:•UseinPregnancy:Fetalharmcanoccurwhenadministeredtoapregnant2•100mg/minfusedintravenouslyover30minuteson

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。